These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15282681)

  • 1. Adherence to deferoxamine therapy: heeding Hippocrates and Osler.
    Olivieri NF
    Am J Hematol; 2004 Aug; 76(4):415-6. PubMed ID: 15282681
    [No Abstract]   [Full Text] [Related]  

  • 2. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of the "difficult" iron-overloaded patient.
    Martin MB
    Ann N Y Acad Sci; 2005; 1054():516-7. PubMed ID: 16339711
    [No Abstract]   [Full Text] [Related]  

  • 6. Compliance with therapy in Cooley's anaemia.
    Vullo C; Di Palma A
    Prog Clin Biol Res; 1989; 309():43-9. PubMed ID: 2780749
    [No Abstract]   [Full Text] [Related]  

  • 7. Overcoming the challenge of patient compliance with iron chelation therapy.
    Cappellini MD
    Semin Hematol; 2005 Apr; 42(2 Suppl 1):S19-21. PubMed ID: 15846581
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron chelation therapy in MDS: does it improve survival?
    Leitch HA
    Leuk Res; 2010 Jul; 34(7):852-3. PubMed ID: 20346508
    [No Abstract]   [Full Text] [Related]  

  • 9. Iron chelation therapy for patients with sickle cell disease and iron overload.
    Inati A; Khoriaty E; Musallam KM; Taher AT
    Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
    [No Abstract]   [Full Text] [Related]  

  • 10. An update on disordered iron metabolism and iron overload.
    Ward R
    Hematology; 2010 Oct; 15(5):311-7. PubMed ID: 20863426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update.
    Franchini M; Gandini G; Veneri D; Aprili G
    Blood; 2004 Jan; 103(2):747-8. PubMed ID: 14702291
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac complications in homozygous beta-thalassemia.
    Wonke B; Hoffbrand AV; Aldouri MA; Ward SE
    Prog Clin Biol Res; 1989; 309():51-6. PubMed ID: 2780750
    [No Abstract]   [Full Text] [Related]  

  • 15. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 18. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.
    Mudiyanse RM
    Hemoglobin; 2006; 30(2):275-89. PubMed ID: 16798653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent acquisitions in the management of iron overload.
    Franchini M
    Ann Hematol; 2005 Oct; 84(10):640-5. PubMed ID: 16025271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.